EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations

Elizabeth Titova iD, Veronica W Kan, Tara Lozy iD, Andrew Ip, Kileen Shier iD, Vittal P Prakash, Meghan Starolis, Sara Ansari, Kira Goldgirsh, Seoyeon Kim, Michael C Pelliccia, Aamirah Mccutchen und 5 weitere

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.02050-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Elizabeth Titova und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Hematologic Neoplasms, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer patients are at risk for severe coronavirus disease 2019 (COVID-19) outcomes due to impaired immune responses. However, the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is inadequately characterized in this population. We hypothesized that cancer vs non-cancer individuals would mount less robust humoral and/or cellular vaccine-induced immune SARS-CoV-2 responses. Receptor binding domain (RBD) and SARS-CoV-2 spike protein antibody levels and T-cell responses were assessed in immunocompetent individuals with no underlying disorders ( n = 479) and immunocompromised individuals ( n = 115). All 594 individuals were vaccinated and of varying COVID-19 statuses (i.e., not known to have been infected, previously infected, or “Long-COVID”). Among immunocompromised individuals, 59% ( n = 68) had an underlying hematologic malignancy; of those, 46% ( n = 31) of individuals received cancer treatment 1,000 U/mL), and of these, 60% ( n = 281) and 44% ( n = 41), respectively, also had elevated T-cell responses. Composite T-cell responses were higher in individuals previously infected with SARS-CoV-2 or those diagnosed with Long-COVID compared to uninfected individuals. T-cell responses varied between immunocompetent vs carcinoma ( n = 12) cohorts ( P < 0.01) but not in immunocompetent vs hematologic malignancy cohorts. Most SARS-CoV-2 vaccinated individuals mounted robust cellular and/or humoral responses, though higher immunogenicity was observed among the immunocompetent compared to cancer populations. The study suggests B-cell targeted therapies suppress antibody responses, but not T-cell responses, to SARS-CoV-2 vaccination. Thus, vaccination continues to be an effective way to induce humoral and cellular immune responses as a likely key preventive measure against infection and/or subsequent more severe adverse outcomes. IMPORTANCE The study was prompted by a desire to better assess the immune status of patients among our cancer host cohort, one of the largest in the New York metropolitan region. Hackensack Meridian Health is the largest healthcare system in New Jersey and cared for more than 75,000 coronavirus disease 2019 patients in its hospitals. The John Theurer Cancer Center sees more than 35,000 new cancer patients a year and performs more than 500 hematopoietic stem cell transplants. As a result, the work was undertaken to assess the effectiveness of vaccination in inducing humoral and cellular responses within this demographic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHematologic NeoplasmsSpike Glycoprotein, CoronavirusHumansSARS-CoV-2Post-Acute COVID-19 SyndromeCOVID-19 VaccinesVaccinationImmunity, CellularAntibodies, ViralImmunity, Humoral

Stichwörter der Autor:innen

SARS-CoV-2cancerimmune responseimmunocompromisedpost-vaccination

Substanzen

spike protein, SARS-CoV-2COVID-19 VaccinesAntibodies, ViralSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
  • John Theurer Cancer Center, Hackensack, New Jersey, USA.
  • Hackensack Meridian School of Medicine, Nutley, New Jersey, USA.
  • Quest Diagnostics, Secaucus, New Jersey, USA.
  • Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.

ORCID-Profile: Elizabeth Titova, Tara Lozy, Kileen Shier, David S Perlin

Zitieren

APA

Titova, E., Kan, V. W., Lozy, T., Ip, A., Shier, K., Prakash, V. P., Starolis, M., Ansari, S., Goldgirsh, K., Kim, S., Pelliccia, M. C., Mccutchen, A., Megalla, M., Gunning, T. S., Kaufman, H. W., Meyer, W. A., & Perlin, D. S. (2024). Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02050-23

Vancouver

Titova E, Kan VW, Lozy T, Ip A, Shier K, Prakash VP, et al. Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations. Microbiology Spectrum. 2024. doi:10.1128/spectrum.02050-23

BibTeX
@article{Titova2024,
  author = {Titova, Elizabeth and Kan, Veronica W and Lozy, Tara and Ip, Andrew and Shier, Kileen and Prakash, Vittal P and Starolis, Meghan and Ansari, Sara and Goldgirsh, Kira and Kim, Seoyeon and Pelliccia, Michael C and Mccutchen, Aamirah and Megalla, Martinus and Gunning, Thomas S and Kaufman, Harvey W and Meyer, William A and Perlin, David S},
  title = {Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.02050-23}
}
Kostenlos starten →